Instrument Inactif

Communiqués Nightstar Therapeutics PLC

Actions

US65413A1016

Recherche biotechnologique et médicale

Communiqués

05/06/19	Nightstar Therapeutics plc Court Approval Received in Connection With Acquisition by Biogen	GL
29/05/19	Nightstar Therapeutics plc Update to Timetable Relating to the Acquisition by Biogen	GL
08/05/19	Nightstar Therapeutics PLC Shareholders Approve Scheme of Arrangement for Acquisition By Biogen at General Meeting and Court Meeting Held on 8 May 2019	GL
04/03/19	Nightstar Therapeutics plc reaches agreement to be acquired by Biogen	GL
13/11/18	Nightstar Announces Planned Initiation of Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP and Reports Third Quarter 2018 Financial Results	GL
04/10/18	Nightstar Therapeutics to Present at Chardan Genetic Medicines Conference	GL
01/10/18	Nightstar Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa	GL
28/09/18	Nightstar Announces Pricing of Public Offering	GL
25/09/18	Nightstar Announces Proposed Public Offering of American Depositary Shares	GL
13/09/18	Nightstar Appoints Strategic Biotechnology Executive Paula Cobb to its Board of Directors	GL
13/08/18	Nightstar Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights	GL
07/08/18	Nightstar Therapeutics to Present at Wedbush PacGrow Healthcare Conference	GL
14/06/18	Nightstar Therapeutics : Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for NSR-REP1 in Choroideremia	GL
14/06/18	Nightstar Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for NSR-REP1 in Choroideremia	GL
06/06/18	Nightstar Therapeutics : Reports First Quarter 2018 Financial Results and Acceleration of Preliminary NSR-RPGR Readout to Third Quarter 2018	GL
31/05/18	Nightstar Therapeutics : to Present at Jefferies 2018 Global Healthcare Conference	GL
30/04/18	Nightstar Therapeutics : to Present at the Deutsche Bank 43rd Annual Health Care Conference	GL
23/04/18	Nightstar Therapeutics : to Present New Data in Choroideremia at the ARVO 2018 Annual Meeting	GL
03/04/18	Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights	GL
05/03/18	Nightstar Therapeutics : Announces Initiation of STAR Phase 3 Registrational Trial for NSR-REP1 in Choroideremia	GL
07/12/17	Nightstar Therapeutics : to Participate in BMO Prescriptions for Success Healthcare Conference	GL
08/11/17	Nightstar Expands Pipeline with Novel Gene Therapy for the Treatment of Stargardt Disease	GL
30/10/17	Nightstar Therapeutics : to Participate in Multiple Conferences in November	GL
02/10/17	Nightstar Therapeutics : Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares	GL
02/10/17	Nightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares	GL